Evaluation of Neuroprotective Effect of Gut Microbe in Parkinson's Disease: An In Silico and In Vivo Approach
NeuroMolecular Medicine · 2024
DOI: 10.1007/s12017-024-08799-w ↗Kurz gefasst
Fachartikel in der Zeitschrift NeuroMolecular Medicine, 2024. Verfasst von Kanika Bhardwaj und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, IIS (Deemed to be University), Jaipur, Rajasthan, 302020, India. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics, alpha-Synuclein, Escherichia coli. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Parkinson's disease is a progressive neurodegenerative disorder marked by the death of dopaminergic neurons in the substantia nigra region of the brain. Aggregation of alpha-synuclein (α-synuclein) is a contributing factor to Parkinson's disease pathogenesis. The objective of this study is to investigate the neuroprotective effects of gut microbes on α-synuclein aggregation using both in silico and in vivo approaches. We focussed on the interaction between α-synuclein and metabolites released by gut bacteria that protect from PD. We employed three probiotic microbe strains against α-synuclein protein: Lactobacillus casei, Escherichia coli, and Bacillus subtilis, with their chosen PDB IDs being Dihydrofolate reductase (3DFR), methionine synthetase (6BM5), and tryptophanyl-tRNA synthetase (3PRH), respectively. Using HEX Dock 6.0 software, we examined the interactions between these proteins. Among the various metabolites, methionine synthetase produced by E. coli showed potential interactions with α-synuclein. To further evaluate the neuroprotective benefits of E. coli, an in vivo investigation was performed using a rotenone-induced Parkinsonian mouse model. The motor function of the animals was assessed through behavioural tests, and oxidative stress and neurotransmitter levels were also examined. The results demonstrated that, compared to the rotenone-induced PD mouse model, the rate of neurodegeneration was considerably reduced in mice treated with E. coli. Additionally, histopathological studies provided evidence of the neuroprotective effects of E. coli. In conclusion, this study lays the groundwork for future research, suggesting that gut bacteria may serve as potential therapeutic agents in the development of medications to treat Parkinson's disease. fig. 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Zoology, IIS (Deemed to be University), Jaipur, Rajasthan, 302020, India.
- Department of Zoology, IIS (Deemed to be University), Jaipur, Rajasthan, 302020, India. neelukanwar.rajawat@iisuniv.ac.in.
- Department of Zoology, University of Rajasthan, Jaipur, Rajasthan, 302020, India.
- Birla Institute of Scientific Research, Jaipur, Rajasthan, 302020, India.
ORCID-Profile: Neelu Kanwar Rajawat
Zitieren
APA
Bhardwaj, K., Rajawat, N. K., Mathur, N., & Kaushik, A. (2024). Evaluation of Neuroprotective Effect of Gut Microbe in Parkinson's Disease: An In Silico and In Vivo Approach. NeuroMolecular Medicine. https://doi.org/10.1007/s12017-024-08799-w
Vancouver
Bhardwaj K, Rajawat NK, Mathur N, Kaushik A. Evaluation of Neuroprotective Effect of Gut Microbe in Parkinson's Disease: An In Silico and In Vivo Approach. NeuroMolecular Medicine. 2024. doi:10.1007/s12017-024-08799-w
BibTeX
@article{Bhardwaj2024,
author = {Bhardwaj, Kanika and Rajawat, Neelu Kanwar and Mathur, Nupur and Kaushik, Aviral},
title = {Evaluation of Neuroprotective Effect of Gut Microbe in Parkinson's Disease: An In Silico and In Vivo Approach},
journal = {NeuroMolecular Medicine},
year = {2024},
doi = {10.1007/s12017-024-08799-w}
}
EUVIMED